Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
With the first readouts of trials of antibodies against COVID-19 appearing and others coming thick and fast, Nature Biotechnology asked a group of experts to comment on the challenges and timelines for these products.
